Evidence map›Paper›PMID 37567986›Full record

ArticleJournal of cancer research and clinical oncology2023

Predictive value of

Jianlin Wang, Xiaopeng Yu, Aiqi Shi, Long Xie, Liqun Huang, Yingrui Su, Jinshun Zha, Jiangyan Liu

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Application ofWorld journal of gastrointestinal surgery · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jianlin Wang *Department of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362018, People's Republic of China.
Xiaopeng Yu *Department of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362018, People's Republic of China.
Aiqi ShiDepartment of Nuclear Medicine, Lanzhou University Second Hospital, Cuiyingmen No. 82, Chengguan District, Lanzhou, 730030, People's Republic of China.
Long XieDepartment of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362018, People's Republic of China.
Liqun HuangDepartment of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362018, People's Republic of China.
Yingrui SuDepartment of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362018, People's Republic of China.
Jinshun ZhaDepartment of Nuclear Medicine, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362018, People's Republic of China.
Jiangyan LiuDepartment of Nuclear Medicine, Lanzhou University Second Hospital, Cuiyingmen No. 82, Chengguan District, Lanzhou, 730030, People's Republic of China. ery_liujy@lzu.edu.cn.
Second Affiliated Hospital of Fujian Medical University · CNFujian Medical University · CNLanzhou University · CNLanzhou University Second Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe aimed to investigate the predictive value of pre-treatment

methodsSeventy-one patients with gastric cancer were included. All patients underwent

resultsA total of 71 patients with gastric cancer, including 57 (80.3%) males and 14 (19.7%) females, had a mean age of 61 ± 10 years; disease progression occurred in 27 (38.0%) patients and death occurred in 24 (33.8%) patients. Multivariate Cox regression analysis showed that HI-1 alone was a common independent risk factor for PFS (HR: 1.183; 95% CI: 1.010-1.387, P < 0.05) and OS (HR: 1.214; 95% CI: 1.016-1.450, P < 0.05) in patients with gastric cancer. A nomogram created based on the results of Cox regression analysis increased the net clinical benefit for patients. Considering disease progression as a positive event, patients were divided into low-, intermediate-, and high-risk groups, and Kaplan-Meier survival analysis showed that there were significant differences in PFS among the three groups. When death was considered a positive event and patients were included in the low- and high-risk groups, there were significant differences in OS between the two groups.

conclusionThe heterogeneity index HI-1 of primary gastric cancer lesions is an independent risk factor for patient prognosis. A nomogram of prognostic prediction models constructed for each independent factor can increase the net clinical benefit and stratify the risk level of patients, providing a reference for guiding individualized patient treatment.

Indexed as

Positron Emission Tomography Computed TomographyStomach NeoplasmsAgedDisease ProgressionFemaleFluorodeoxyglucose F18HumansMaleMiddle AgedPrognosisRadiopharmaceuticalsRetrospective StudiesTumor BurdenFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTGastric cancerMetabolic heterogeneityMetabolic parametersPrognosis

Identifiers

PMID37567986
PMCPMC11796797
OpenAlexW4385778726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.